Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.
The final milestone in the current roadmap is D19, projected for 2028. This device will incorporate three additional blood ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
This story by Public Health Watch is part of a collaboration with Univision 45 in Houston. HIGHLANDS, Texas—Eight months ago, ...
Detailed price information for Kintavar Exploration Inc (KTR-X) from The Globe and Mail including charting and trades.
The post 2026 GWM Haval H6 PHEV review: Australian first drive appeared first on Drive. Plug-in hybrid (PHEV) technology has ...
Antimony has gone from niche to indispensable. Driven by China’s export ban, supply constraints, and urgency in US, antimony is red-hot.
U.S. consumer confidence fell in October, in line with expectations that economic activity would slow in the fourth quarter as the boost from fiscal stimulus fades.
Consumer confidence dropped sharply in October in three U.S. states considered crucial for Republican President Donald Trump's re-election as fears about the economy's outlook mounted, according to a ...
In The Lancet Gastroenterology & Hepatology, Elyse Thakur and colleagues1 present an update of their 2020 systematic review and network meta-analysis on the efficacy of behavioural therapies for ...
Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal ...
Key messages • Blood pressure-lowering medications lower the chance of death and probably reduce heart attacks and strokes in people with hypertension (high blood pressure) 60 y ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback